From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

Speciality: Oncology

Description:

Welcome to this insightful educational series presented by Dr. Nitin, Dr. Riyaz, and Dr. Eesha. We are thrilled to bring you an in-depth look at some of the most critical advancements shaping the landscape of hematologic malignancies. In this first installment, we begin our journey through the complex terrain of adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) - a condition that continues to challenge clinicians and patients alike. Our goal is to break down the science, spotlight evolving treatment strategies, and bring forward real-world relevance to current evidence-based practices.

Part 1 of this series focuses on a game-changing concept in leukemia care - Minimal Residual Disease (MRD) negativity. Often referred to as “chasing the invisible,” MRD refers to the small number of leukemic cells that may remain after treatment, undetectable by conventional methods. Achieving MRD negativity has emerged as a key goal, with significant implications for prognosis, treatment planning, and long-term remission. We’ll explore how cutting-edge therapies - like CAR-T cell therapy, blinatumomab, and inotuzumab ozogamicin - are enabling deeper remissions, and how MRD is guiding personalized treatment pathways in adult R/R B-ALL. From diagnostics to clinical decision-making, MRD is redefining outcomes in the fight against this aggressive disease.

Thank you for joining us in this first part of our series. We hope this session brings clarity, inspiration, and renewed perspective on the path from relapse to remission. Stay tuned for more episodes as we continue to explore advanced strategies, expert opinions, and real-world applications in hematology and oncology. Keep watching - insightful learning is just getting started.

See More Webinars @ Hidoc Webinars